Skip to main content
Fig. 7 | BMC Medicine

Fig. 7

From: Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Fig. 7

Mechanisms of PTPRD regulating tumor immune microenvironment. a Estimation of 22 immune cell infiltrations of PTPRD WT, phosphatase-mut, and other-mut (left panel) or PTPRD low and high (right panel). b Heatmap depicting the log2-fold change in the expression level of immune-related genes across PTPRD mutation types (FC1: other-mut/WT, FC2: phosphatase-mut/WT, FC3: phosphatase-mut/other-mut). Blue indicated downregulation and red indicated upregulation. c PTPRD expressions across PTPRD mutations in TCGA-LUAD. d GSEA enrichments in comparisons between PTPRD low and high. e, f Correlation between PTPRD and genes among immune checkpoint signature (e) and T effector and IFN-γ gene signature (f). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us